Market Research Logo

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2015

Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Review, H2 2015’, provides an overview of the Non Alcoholic Fatty Liver Disease (NAFLD)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Non Alcoholic Fatty Liver Disease (NAFLD) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Non Alcoholic Fatty Liver Disease (NAFLD)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Non Alcoholic Fatty Liver Disease (NAFLD) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Non Alcoholic Fatty Liver Disease (NAFLD) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Non Alcoholic Fatty Liver Disease (NAFLD) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Non Alcoholic Fatty Liver Disease (NAFLD)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Non Alcoholic Fatty Liver Disease (NAFLD) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Non Alcoholic Fatty Liver Disease (NAFLD) Overview
Therapeutics Development
Pipeline Products for Non Alcoholic Fatty Liver Disease (NAFLD) - Overview
Pipeline Products for Non Alcoholic Fatty Liver Disease (NAFLD) - Comparative Analysis
Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics under Development by Companies
Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics under Investigation by Universities/Institutes
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Non Alcoholic Fatty Liver Disease (NAFLD) - Products under Development by Companies
Non Alcoholic Fatty Liver Disease (NAFLD) - Products under Investigation by Universities/Institutes
Non Alcoholic Fatty Liver Disease (NAFLD) - Companies Involved in Therapeutics Development
Arisaph Pharmaceuticals, Inc.
Conatus Pharmaceuticals Inc.
Daewoong Pharmaceutical Co., Ltd.
Dimerix Bioscience Pty Ltd
Dr. Falk Pharma GmbH
DURECT Corporation
Galmed International Ltd.
Gilead Sciences, Inc.
Huons Co., Ltd.
Kyorin Pharmaceutical Co., Ltd.
Metabolic Solutions Development Company, LLC
Novartis AG
Raptor Pharmaceuticals Corp.
TCM Biotech International Corp
Tobira Therapeutics, Inc.
Verva Pharmaceuticals Limited
Zafgen Inc.
Zydus Cadila Healthcare Limited
Non Alcoholic Fatty Liver Disease (NAFLD) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Aramchol - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ARI-3037MO - Drug Profile
Product Description
Mechanism of Action
R&D Progress
C-10 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cenicriviroc mesylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
cysteamine DR - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DMX-300 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Drugs to Inhibit ABHD6 for Gastrointestinal and Metabolic Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DUR-928 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
DWP-10292 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
emricasan - Drug Profile
Product Description
Mechanism of Action
R&D Progress
HU-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
KDT-501 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MAT-8800 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MB-12066 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
methazolamide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MN-002 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MSDC-0602 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
norursodeoxycholic acid - Drug Profile
Product Description
Mechanism of Action
R&D Progress
oltipraz - Drug Profile
Product Description
Mechanism of Action
R&D Progress
pradigastat sodium - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Px-102 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Px-103 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Px-104 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
saroglitazar - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Activate AMPK for Fatty Liver Disease - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit NaCT for Metabolic Diseases - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TCM-606F - Drug Profile
Product Description
Mechanism of Action
R&D Progress
VVP-100-X - Drug Profile
Product Description
Mechanism of Action
R&D Progress
ZGN-839 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Non Alcoholic Fatty Liver Disease (NAFLD) - Recent Pipeline Updates
Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects
Non Alcoholic Fatty Liver Disease (NAFLD) - Product Development Milestones
Featured News & Press Releases
May 18, 2015: DURECT Announces Positive Results from DUR-928 Multi-Dose Phase 1 Study
Apr 23, 2015: Conatus Clinical Results at EASL Meeting Support Emricasan Registration Pathway in NASH
Apr 08, 2015: Conatus Pharmaceuticals to Present Three Emricasan Clinical Results Posters at EASL Meeting
Mar 30, 2015: DURECT Announces Initiation of DUR-928 Multi-Dose Phase 1 Study
Mar 26, 2015: Conatus Announces Successful Top-Line Results From NAFLD/NASH Clinical Trial of Emricasan
Mar 02, 2015: DURECT Announces Epigenomic Regulator Program including a New NAFLD/NASH and Acute Organ Injury Product Candidate in Development
Apr 28, 2014: Galmed Pharmaceuticals Commences Patient Screening for Aramchol Pharmacokinetic and Food Effect Studies
Oct 31, 2012: Phenex Pharma Completes Phase I Studies With FXR-Agonist Px-102
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H2 2015
Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Investigation by Universities/Institutes, H2 2015
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Arisaph Pharmaceuticals, Inc., H2 2015
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Conatus Pharmaceuticals Inc., H2 2015
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Daewoong Pharmaceutical Co., Ltd., H2 2015
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Dimerix Bioscience Pty Ltd, H2 2015
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Dr. Falk Pharma GmbH, H2 2015
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by DURECT Corporation, H2 2015
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Galmed International Ltd., H2 2015
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Gilead Sciences, Inc., H2 2015
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Huons Co., Ltd., H2 2015
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2015
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Metabolic Solutions Development Company, LLC, H2 2015
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Novartis AG, H2 2015
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Raptor Pharmaceuticals Corp., H2 2015
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by TCM Biotech International Corp, H2 2015
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Tobira Therapeutics, Inc., H2 2015
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Verva Pharmaceuticals Limited, H2 2015
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Zafgen Inc., H2 2015
Non Alcoholic Fatty Liver Disease (NAFLD) - Pipeline by Zydus Cadila Healthcare Limited, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Non Alcoholic Fatty Liver Disease (NAFLD) Therapeutics - Recent Pipeline Updates, H2 2015
Non Alcoholic Fatty Liver Disease (NAFLD) - Dormant Projects, H2 2015
List of Figures
Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD), H2 2015
Number of Products under Development for Non Alcoholic Fatty Liver Disease (NAFLD) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Routes of Administration, H2 2015
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report